Screener
Iovance Biotherapeutics, Inc. IOVA Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 9:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091716
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Operating lease liabilities | (2,800) | (5,590) |
| Accounts payable | 4,070 | 2,945 |
| Accrued expenses and other liabilities | (29,653) | 1,969 |
| Net cash used in operating activities | (132,915) | (171,141) |
| Cash Flows from Investing Activities | ||
| Maturities of investments | 135,000 | 210,000 |
| Purchase of investments | (185,607) | (166,619) |
| Purchase of property and equipment | (12,049) | (13,672) |
Item 1.Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Iovance Biotherapeutics, Inc.'s operating cash flow?
- Iovance Biotherapeutics, Inc. (IOVA) reported operating cash flow of -$60.84M in Q2 2026.
- How has Iovance Biotherapeutics, Inc.'s operating cash flow changed year-over-year?
- Iovance Biotherapeutics, Inc.'s operating cash flow increased by 9.8% year-over-year, from -$67.45M to -$60.84M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s operating cash flow?
- Over 4 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s operating cash flow has grown at a 7.3% compound annual growth rate (CAGR), from -$227.94M to -$302.41M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Iovance Biotherapeutics, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude